Luye Pharma Group (HKG:2186) raised net proceeds of $98.6 million from the issuance of the first tranche of $100 million 5.85% convertible bonds due 2025, a Wednesday Hong Kong bourse filing said.
The bonds have an initial conversion price of HK$3.672 per share, subject to certain conditions, the filing said.
The company plans to use the net proceeds to settle some of its debts, for research and development, and for general corporate purposes.
The bonds are expected to be listed in Singapore on Nov. 1.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments